74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Voyager Therapeutics Inc
Closed
4.27 -0.47
Overview
Share price change
24h
Min
4.21
Max
4.33
Income | 1.1M -9M |
|---|---|
Sales | -4.9M 25M |
P/E Sector Avg | 6.515 73.394 |
EPS | -0.16 |
Profit margin | -36.721 |
Employees | 162 |
EBITDA | 985K -13M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +276.74 upside |
Next Earnings | 26 Feb 2025 |
|---|
Market Cap | 235M |
|---|---|
Previous open | 4.74 |
Previous close | 4.27 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Voyager Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Voyager Therapeutics Inc Forecast
Price Target
By TipRanks
276.74% upside
12 Months Forecast
Average 16.2 USD 276.74%
High 30 USD
Low 9 USD
Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
